Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis
Background & Aims - Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[September 2020]
|
| In: |
Clinical gastroenterology and hepatology
Year: 2020, Volume: 18, Issue: 10 |
| ISSN: | 1542-7714 |
| DOI: | 10.1016/j.cgh.2020.02.014 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.cgh.2020.02.014 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S1542356520301828 
|
| Author Notes: | Charlotte Rose Hawkey Hedin, Gina Sado, Nelson Ndegwa, Ellina Lytvyak, Andrew Mason, Aldo Montano-Loza, Alessio Gerussi, Francesca Saffioti, Douglas Thorburn, Emma Nilsson, Geir Larsson, Bjørn A. Moum, Kim N. van Munster, Cyriel Y. Ponsioen, Cynthia Levy, Nicholas F. Nogueira, Christopher L. Bowlus, Neta Gotlieb, Oren Shibolet, Kate D. Lynch, Roger W. Chapman, Christian Rupp, Mette Vesterhus, Kristin K. Jørgensen, Fredrik Rorsman, Christoph Schramm, João Sabino, Severine Vermeire, Alessandra Zago, Nora Cazzagon, Hanns-Ulrich Marschall, Henriette Ytting, Karima Ben Belkacem, Olivier Chazouilleres, Sven Almer, International PSC Study Group, Annika Bergquist |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1733940642 | ||
| 003 | DE-627 | ||
| 005 | 20240407193259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200929s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cgh.2020.02.014 |2 doi | |
| 035 | |a (DE-627)1733940642 | ||
| 035 | |a (DE-599)KXP1733940642 | ||
| 035 | |a (OCoLC)1341365124 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hedin, Charlotte |e VerfasserIn |0 (DE-588)1206385596 |0 (DE-627)1692400347 |4 aut | |
| 245 | 1 | 0 | |a Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis |c Charlotte Rose Hawkey Hedin, Gina Sado, Nelson Ndegwa, Ellina Lytvyak, Andrew Mason, Aldo Montano-Loza, Alessio Gerussi, Francesca Saffioti, Douglas Thorburn, Emma Nilsson, Geir Larsson, Bjørn A. Moum, Kim N. van Munster, Cyriel Y. Ponsioen, Cynthia Levy, Nicholas F. Nogueira, Christopher L. Bowlus, Neta Gotlieb, Oren Shibolet, Kate D. Lynch, Roger W. Chapman, Christian Rupp, Mette Vesterhus, Kristin K. Jørgensen, Fredrik Rorsman, Christoph Schramm, João Sabino, Severine Vermeire, Alessandra Zago, Nora Cazzagon, Hanns-Ulrich Marschall, Henriette Ytting, Karima Ben Belkacem, Olivier Chazouilleres, Sven Almer, International PSC Study Group, Annika Bergquist |
| 264 | 1 | |c [September 2020] | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.09.2020 | ||
| 520 | |a Background & Aims - Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. - Methods - We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. - Results - Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P = .035). Factors associated with lower ALP were normal ALP at baseline (P < .01), treatment with adalimumab (P = .090), and treatment in Europe (P = .083). - Conclusions - In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further. | ||
| 650 | 4 | |a Anti-Inflammatory | |
| 650 | 4 | |a Hepatic | |
| 650 | 4 | |a Intestine | |
| 650 | 4 | |a Liver Transplantation | |
| 700 | 1 | |a Sado, Gina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ndegwa, Nelson |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lytvyak, Ellina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mason, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Montano-Loza, Aldo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gerussi, Alessio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Saffioti, Francesca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thorburn, Douglas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nilsson, Emma |e VerfasserIn |4 aut | |
| 700 | 1 | |a Larsson, Geir |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moum, Bjørn A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Munster, Kim N. van |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ponsioen, Cyriel Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Levy, Cynthia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nogueira, Nicholas F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bowlus, Christopher L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gotlieb, Neta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shibolet, Oren |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lynch, Kate D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chapman, Roger W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rupp, Christian |d 1982- |e VerfasserIn |0 (DE-588)1023613190 |0 (DE-627)718110765 |0 (DE-576)367149435 |4 aut | |
| 700 | 1 | |a Vesterhus, Mette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jørgensen, Kristin K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rorsman, Fredrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schramm, Christoph |d 1969- |e VerfasserIn |0 (DE-588)1027343740 |0 (DE-627)728977621 |0 (DE-576)372911048 |4 aut | |
| 700 | 1 | |a Sabino, João |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vermeire, Severine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zago, Alessandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cazzagon, Nora |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marschall, Hanns-Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ytting, Henriette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ben Belkacem, Karima |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chazouilleres, Olivier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Almer, Sven |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bergquist, Annika |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology |d New York, NY : Elsevier Science, 2003 |g 18(2020,10) Seite 2295-2304, e1-e2 |h Online-Ressource |w (DE-627)363139893 |w (DE-600)2102638-5 |w (DE-576)339260823 |x 1542-7714 |7 nnas |a Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis |
| 773 | 1 | 8 | |g volume:18 |g year:2020 |g number:10 |g extent:12 |a Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cgh.2020.02.014 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1542356520301828 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200929 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1023613190 |a Rupp, Christian |m 1023613190:Rupp, Christian |d 910000 |d 910100 |d 50000 |e 910000PR1023613190 |e 910100PR1023613190 |e 50000PR1023613190 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 22 | ||
| 999 | |a KXP-PPN1733940642 |e 3763871977 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"recId":"363139893","id":{"issn":["1542-7714"],"eki":["363139893"],"zdb":["2102638-5"]},"pubHistory":["1.2003 -"],"origin":[{"publisherPlace":"New York, NY","dateIssuedDisp":"2003-","publisher":"Elsevier Science","dateIssuedKey":"2003"}],"note":["Gesehen am 01.03.11"],"part":{"issue":"10","year":"2020","text":"18(2020,10) Seite 2295-2304, e1-e2","extent":"12","volume":"18"},"physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"subtitle":"the official clinical practice journal of the American Gastroenterological Association","title":"Clinical gastroenterology and hepatology","title_sort":"Clinical gastroenterology and hepatology"}],"disp":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitisClinical gastroenterology and hepatology","language":["eng"]}],"physDesc":[{"extent":"12 S."}],"note":["Gesehen am 29.09.2020"],"language":["eng"],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"[September 2020]"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"roleDisplay":"VerfasserIn","given":"Charlotte","display":"Hedin, Charlotte","family":"Hedin","role":"aut"},{"role":"aut","family":"Sado","roleDisplay":"VerfasserIn","given":"Gina","display":"Sado, Gina"},{"given":"Nelson","roleDisplay":"VerfasserIn","display":"Ndegwa, Nelson","family":"Ndegwa","role":"aut"},{"family":"Lytvyak","roleDisplay":"VerfasserIn","given":"Ellina","display":"Lytvyak, Ellina","role":"aut"},{"family":"Mason","roleDisplay":"VerfasserIn","given":"Andrew","display":"Mason, Andrew","role":"aut"},{"role":"aut","display":"Montano-Loza, Aldo","roleDisplay":"VerfasserIn","given":"Aldo","family":"Montano-Loza"},{"family":"Gerussi","given":"Alessio","roleDisplay":"VerfasserIn","display":"Gerussi, Alessio","role":"aut"},{"family":"Saffioti","roleDisplay":"VerfasserIn","display":"Saffioti, Francesca","given":"Francesca","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Douglas","display":"Thorburn, Douglas","family":"Thorburn"},{"role":"aut","family":"Nilsson","roleDisplay":"VerfasserIn","display":"Nilsson, Emma","given":"Emma"},{"family":"Larsson","roleDisplay":"VerfasserIn","display":"Larsson, Geir","given":"Geir","role":"aut"},{"role":"aut","given":"Bjørn A.","roleDisplay":"VerfasserIn","display":"Moum, Bjørn A.","family":"Moum"},{"roleDisplay":"VerfasserIn","display":"Munster, Kim N. van","given":"Kim N. van","family":"Munster","role":"aut"},{"role":"aut","given":"Cyriel Y.","roleDisplay":"VerfasserIn","display":"Ponsioen, Cyriel Y.","family":"Ponsioen"},{"role":"aut","family":"Levy","roleDisplay":"VerfasserIn","given":"Cynthia","display":"Levy, Cynthia"},{"role":"aut","given":"Nicholas F.","roleDisplay":"VerfasserIn","display":"Nogueira, Nicholas F.","family":"Nogueira"},{"role":"aut","family":"Bowlus","roleDisplay":"VerfasserIn","display":"Bowlus, Christopher L.","given":"Christopher L."},{"role":"aut","roleDisplay":"VerfasserIn","given":"Neta","display":"Gotlieb, Neta","family":"Gotlieb"},{"role":"aut","family":"Shibolet","roleDisplay":"VerfasserIn","given":"Oren","display":"Shibolet, Oren"},{"display":"Lynch, Kate D.","roleDisplay":"VerfasserIn","given":"Kate D.","family":"Lynch","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Chapman, Roger W.","given":"Roger W.","family":"Chapman","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Christian","display":"Rupp, Christian","family":"Rupp","role":"aut"},{"role":"aut","family":"Vesterhus","roleDisplay":"VerfasserIn","given":"Mette","display":"Vesterhus, Mette"},{"family":"Jørgensen","roleDisplay":"VerfasserIn","display":"Jørgensen, Kristin K.","given":"Kristin K.","role":"aut"},{"role":"aut","given":"Fredrik","roleDisplay":"VerfasserIn","display":"Rorsman, Fredrik","family":"Rorsman"},{"given":"Christoph","roleDisplay":"VerfasserIn","display":"Schramm, Christoph","family":"Schramm","role":"aut"},{"family":"Sabino","display":"Sabino, João","roleDisplay":"VerfasserIn","given":"João","role":"aut"},{"family":"Vermeire","display":"Vermeire, Severine","roleDisplay":"VerfasserIn","given":"Severine","role":"aut"},{"family":"Zago","given":"Alessandra","roleDisplay":"VerfasserIn","display":"Zago, Alessandra","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Nora","display":"Cazzagon, Nora","family":"Cazzagon"},{"roleDisplay":"VerfasserIn","display":"Marschall, Hanns-Ulrich","given":"Hanns-Ulrich","family":"Marschall","role":"aut"},{"display":"Ytting, Henriette","roleDisplay":"VerfasserIn","given":"Henriette","family":"Ytting","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Karima","display":"Ben Belkacem, Karima","family":"Ben Belkacem"},{"family":"Chazouilleres","given":"Olivier","roleDisplay":"VerfasserIn","display":"Chazouilleres, Olivier","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Almer, Sven","given":"Sven","family":"Almer"},{"family":"Bergquist","display":"Bergquist, Annika","roleDisplay":"VerfasserIn","given":"Annika","role":"aut"}],"title":[{"title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","title_sort":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis"}],"id":{"eki":["1733940642"],"doi":["10.1016/j.cgh.2020.02.014"]},"recId":"1733940642","name":{"displayForm":["Charlotte Rose Hawkey Hedin, Gina Sado, Nelson Ndegwa, Ellina Lytvyak, Andrew Mason, Aldo Montano-Loza, Alessio Gerussi, Francesca Saffioti, Douglas Thorburn, Emma Nilsson, Geir Larsson, Bjørn A. Moum, Kim N. van Munster, Cyriel Y. Ponsioen, Cynthia Levy, Nicholas F. Nogueira, Christopher L. Bowlus, Neta Gotlieb, Oren Shibolet, Kate D. Lynch, Roger W. Chapman, Christian Rupp, Mette Vesterhus, Kristin K. Jørgensen, Fredrik Rorsman, Christoph Schramm, João Sabino, Severine Vermeire, Alessandra Zago, Nora Cazzagon, Hanns-Ulrich Marschall, Henriette Ytting, Karima Ben Belkacem, Olivier Chazouilleres, Sven Almer, International PSC Study Group, Annika Bergquist"]}} | ||
| SRT | |a HEDINCHARLEFFECTSOFT2020 | ||